Increased risk of rehospitalisation and death in older hospital patients at risk of malnutrition: A cohort study.

Objectives: The aim of the study was to investigate associations between risk of malnutrition and risk of rehospitalisation and death in older hospital patients, and whether the possible associations were modified by age, gender, comorbidity or Ambulatory Care Sensitive Conditions (ACSCs).

Design: Prospective cohort study.

Setting: Somatic hospital in Western Norway.

Craving induction through virtual reality cue-exposure for patients with alcohol dependence in rehabilitation treatment.

New therapeutic approaches for alcohol dependence (AD) include virtual reality (VR)-based treatments offering scalable options for cue exposure (CE), a well-established strategy in cognitive behavioral therapy. This study aimed to evaluate the feasibility and tolerability of a new VR-CE paradigm. On an explorative basis, factors influencing the induction of craving were examined.

Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2-Stained Clinical Specimens in Breast Cancer.

Context.—: Precise determination of biomarker status is necessary for clinical trial enrollment and endpoint analyses, as well as for optimal treatment determination in real-world practice. However, variabilities may be introduced into this process due to the processing of clinical specimens by different laboratories and assessment by distinct pathologists.

Correlation of Functional and Structural Outcomes with Serum Antibody Profiles in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial.

Age-related macular degeneration (AMD) is a multifactorial disorder, and there is growing evidence of immunological involvement in its pathogenesis. To address this, we aimed to identify biomarker candidates related to retinal antigens in patients with neovascular AMD treated with ranibizumab and healthy subjects. This study was designed as a prospective, open, parallel-group, interventional, single-center phase IV trial.